Automated silver-enhanced in situ hybridization for evaluation of HER2 gene status in breast carcinoma: Comparison with fluorescence in situ hybridization and immunohistochemistry

Korean Journal of Pathology

Volumn 44, Issue 1, 2010, Pages 28-34

  Sung, Woo Jung ^a   Park, Seok Ju ^a   Gu, Mi Jin ^b   Bae, Young Kyung ^a  

^a Yeungnam University College of Medicine   (South Korea)

^b Daegu Fatima Hospital   (South Korea)

Author keywords

Breast neoplasms; Fluorescence; HER2 protein; Human; In situ hybridization; Silver

Indexed keywords

EID: 77955036869     PISSN: 17381843     EISSN: None     Source Type: Journal    
DOI: 10.4132/KoreanJPathol.2010.44.1.28     Document Type: Article

References (15)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
2. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25: 5287-312.
3. Practice Recommendations of Breast Cancer 2008 [Internet]. Seoul: Korean Breast Cancer Society, c2009 [cited 2009 Jun 22]. Available from: http://www.kbcs.or.kr.
4. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-45.
5. Francis GD, Jones MA, Beadle GF, Stein SR. Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome. Diagn Mol Pathol 2009; 18: 88-95.
6. Dietel M, Ellis IO, Höfler H, et al. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch 2007; 451: 19-25.
7. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol 1999; 17: 1974-82.
8. Pauletti G, Dandekar S, Rong H, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000; 18: 3651-64.
9. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004; 5: 63-9.
10. Yaziji H, Goldstein LC, Barry TS, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 2004; 291: 1972-7.
11. Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 2009; 27: 1323-33.
12. Bartlett JM, Going JJ, Mallon EA, et al. Evaluating HER2 amplification and overexpression in breast cancer. J Pathol 2001; 195: 422-8.
13. Carbone A, Botti G, Gloghini A, et al. Delineation of HER2 gene status in breast carcinoma by silver in situ hybridization is reproducible among laboratories and pathologists. J Mol Diagn 2008; 10: 527-36.
14. Kim JY, Choi KU, Jung YJ, Kwak HS, Bae YT. Chromogenic in situ hybridization analysis to determinate HER-2/neu status in breast carcinoma. J Korean Surg Soc 2004; 66: 447-53.
15. Troxell ML, Bangs CD, Lawce HJ, et al. Evaluation of Her-2/neu status in carcinomas with amplified chromosome 17 centromere locus. Am J Clin Pathol 2006; 126: 709-16.